{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:20:29Z","timestamp":1790256029138,"version":"4.1.0"},"reference-count":129,"publisher":"Journal of Biomedical Research","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Biomed Res"],"published-print":{"date-parts":[[2024]]},"DOI":"10.7555\/jbr.38.20240009","type":"journal-article","created":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T02:37:45Z","timestamp":1717123065000},"page":"531","source":"Crossref","is-referenced-by-count":11,"title":["Systemic lupus erythematosus therapeutic strategy: From immunotherapy to gut microbiota modulation"],"prefix":"10.7555","volume":"38","author":[{"given":"Vitaly","family":"Chasov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina","family":"Zmievskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Ganeeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvina","family":"Gilyazova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damir","family":"Davletshin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Filimonova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aygul","family":"Valiullina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Kudriaeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emil","family":"Bulatov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4380","reference":[{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.1","doi-asserted-by":"publisher","unstructured":"Fava A, Petri M. Systemic lupus erythematosus: diagnosis and clinical management[J]. <i>J Autoimmun<\/i>, 2019, 96: 1\u201313.","DOI":"10.1016\/j.jaut.2018.11.001"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.2","doi-asserted-by":"publisher","unstructured":"Yaniv G, Twig G, Shor DBA, et al. A volcanic explosion of autoantibodies in systemic lupus erythematosus: a diversity of 180 different antibodies found in SLE patients[J]. <i>Autoimmun Rev<\/i>, 2015, 14(1): 75\u201379.","DOI":"10.1016\/j.autrev.2014.10.003"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.3","doi-asserted-by":"publisher","unstructured":"Felten R, Dervovic E, Chasset F, et al. The 2018 pipeline of targeted therapies under clinical development for systemic lupus erythematosus: a systematic review of trials[J]. <i>Autoimmun Rev<\/i>, 2018, 17(8): 781\u2013790.","DOI":"10.1016\/j.autrev.2018.02.011"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.4","doi-asserted-by":"publisher","unstructured":"Yang B, Zhao M, Wu H, et al. A comprehensive review of biological agents for lupus: beyond single target[J]. <i>Front Immunol<\/i>, 2020, 11: 539797.","DOI":"10.3389\/fimmu.2020.539797"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.5","doi-asserted-by":"publisher","unstructured":"Hafeez U, Gan HK, Scott AM. Monoclonal antibodies as immunomodulatory therapy against cancer and autoimmune diseases[J]. <i>Curr Opin Pharmacol<\/i>, 2018, 41: 114\u2013121.","DOI":"10.1016\/j.coph.2018.05.010"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.6","doi-asserted-by":"publisher","unstructured":"Zhao Q. Bispecific antibodies for autoimmune and inflammatory diseases: clinical progress to date[J]. <i>BioDrugs<\/i>, 2020, 34(2): 111\u2013119.","DOI":"10.1007\/s40259-019-00400-2"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.7","doi-asserted-by":"publisher","unstructured":"Felten R, Scherlinger M, Mertz P, et al. New biologics and targeted therapies in systemic lupus: from new molecular targets to new indications. A systematic review[J]. <i>Joint Bone Spine<\/i>, 2023, 90(2): 105523.","DOI":"10.1016\/j.jbspin.2023.105523"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.8","doi-asserted-by":"publisher","unstructured":"Dubey AK, Handu SS, Dubey S, et al. Belimumab: first targeted biological treatment for systemic lupus erythematosus[J]. <i>J Pharmacol Pharmacother<\/i>, 2011, 2(4): 317\u2013319.","DOI":"10.4103\/0976-500X.85930"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.9","doi-asserted-by":"publisher","unstructured":"Kaminskiy Y, Kuznetsova V, Kudriaeva A, et al. Neglected, yet significant role of FOXP1 in T-cell quiescence, differentiation and exhaustion[J]. <i>Front Immunol<\/i>, 2022, 13: 971045.","DOI":"10.3389\/fimmu.2022.971045"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.10","doi-asserted-by":"publisher","unstructured":"Bergmann C, M\u00fcller F, Distler JHW, et al. Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells[J]. <i>Ann Rheum Dis<\/i>, 2023, 82(8): 1117\u20131120.","DOI":"10.1136\/ard-2023-223952"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.11","doi-asserted-by":"publisher","unstructured":"Mackensen A, M\u00fcller F, Mougiakakos D, et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus[J]. <i>Nat Med<\/i>, 2022, 28(10): 2124\u20132132.","DOI":"10.1038\/s41591-022-02017-5"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.12","doi-asserted-by":"publisher","unstructured":"Kalayci FNC, Ozen S. Possible role of dysbiosis of the gut microbiome in SLE[J]. <i>Curr Rheumatol Rep<\/i>, 2023, 25(12): 247\u2013258.","DOI":"10.1007\/s11926-023-01115-8"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.13","doi-asserted-by":"publisher","unstructured":"Ling Z, Cheng Y, Gao J, et al. Alterations of the fecal and vaginal microbiomes in patients with systemic lupus erythematosus and their associations with immunological profiles[J]. <i>Front Immunol<\/i>, 2023, 14: 1135861.","DOI":"10.3389\/fimmu.2023.1135861"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.14","doi-asserted-by":"publisher","unstructured":"Pan Q, Guo F, Huang Y, et al. Gut microbiota dysbiosis in systemic lupus erythematosus: novel insights into mechanisms and promising therapeutic strategies[J]. <i>Front Immunol<\/i>, 2021, 12: 799788.","DOI":"10.3389\/fimmu.2021.799788"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.15","doi-asserted-by":"publisher","unstructured":"Huang C, Yi P, Zhu M, et al. Safety and efficacy of fecal microbiota transplantation for treatment of systemic lupus erythematosus: an EXPLORER trial[J]. <i>J Autoimmun<\/i>, 2022, 130: 102844.","DOI":"10.1016\/j.jaut.2022.102844"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.16","doi-asserted-by":"publisher","unstructured":"Xin Y, Huang C, Zheng M, et al. Fecal microbiota transplantation in the treatment of systemic lupus erythematosus: what we learnt from the explorative clinical trial[J]. <i>J Autoimmun<\/i>, 2023, 141: 103058.","DOI":"10.1016\/j.jaut.2023.103058"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.17","doi-asserted-by":"publisher","unstructured":"Barber MRW, Drenkard C, Falasinnu T, et al. Global epidemiology of systemic lupus erythematosus[J]. <i>Nat Rev Rheumatol<\/i>, 2021, 17(9): 515\u2013532.","DOI":"10.1038\/s41584-021-00668-1"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.18","doi-asserted-by":"publisher","unstructured":"Mohan C, Putterman C. Genetics and pathogenesis of systemic lupus erythematosus and lupus nephritis[J]. <i>Nat Rev Nephrol<\/i>, 2015, 11(6): 329\u2013341.","DOI":"10.1038\/nrneph.2015.33"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.19","doi-asserted-by":"publisher","unstructured":"Dima A, Jurcut C, Arnaud L. Hydroxychloroquine in systemic and autoimmune diseases: where are we now?[J]. <i>Joint Bone Spine<\/i>, 2021, 88(3): 105143.","DOI":"10.1016\/j.jbspin.2021.105143"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.20","doi-asserted-by":"publisher","unstructured":"Emamikia S, Gentline C, Chatzidionysiou K, et al. Relationship between glucocorticoid dose and adverse events in systemic lupus erythematosus: data from a randomized clinical trial[J]. <i>Scand J Rheumatol<\/i>, 2018, 47(2): 131\u2013140.","DOI":"10.1080\/03009742.2017.1336570"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.21","doi-asserted-by":"publisher","unstructured":"Robinson R. Distinct B cell receptor functions are determined by phosphorylation[J]. <i>PLoS Biol<\/i>, 2006, 4(7): e231.","DOI":"10.1371\/journal.pbio.0040231"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.22","doi-asserted-by":"publisher","unstructured":"Tanaka Y, Kubo S, Iwata S, et al. B cell phenotypes, signaling and their roles in secretion of antibodies in systemic lupus erythematosus[J]. <i>Clin Immunol<\/i>, 2018, 186: 21\u201325.","DOI":"10.1016\/j.clim.2017.07.010"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.23","doi-asserted-by":"publisher","unstructured":"Bossen C, Schneider P. BAFF, APRIL and their receptors: structure, function and signaling[J]. <i>Semin Immunol<\/i>, 2006, 18(5): 263\u2013275.","DOI":"10.1016\/j.smim.2006.04.006"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.24","doi-asserted-by":"publisher","unstructured":"Zollars E, Bienkowska J, Czerkowicz J, et al. BAFF (B cell activating factor) transcript level in peripheral blood of patients with SLE is associated with same-day disease activity as well as global activity over the next year[J]. <i>Lupus Sci Med<\/i>, 2015, 2(1): e000063.","DOI":"10.1136\/lupus-2014-000063"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.25","doi-asserted-by":"publisher","unstructured":"Mackay F, Ambrose C. The TNF family members BAFF and APRIL: the growing complexity[J]. <i>Cytokine Growth Factor Rev<\/i>, 2003, 14(3-4): 311\u2013324.","DOI":"10.1016\/S1359-6101(03)00023-6"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.26","doi-asserted-by":"publisher","unstructured":"Vincent FB, Morand EF, Schneider P, et al. The BAFF\/APRIL system in SLE pathogenesis[J]. <i>Nat Rev Rheumatol<\/i>, 2014, 10(6): 365\u2013373.","DOI":"10.1038\/nrrheum.2014.33"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.27","doi-asserted-by":"publisher","unstructured":"Baker KP, Edwards BM, Main SH, et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator[J]. <i>Arthritis Rheum<\/i>, 2003, 48(11): 3253\u20133265.","DOI":"10.1002\/art.11299"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.28","doi-asserted-by":"publisher","unstructured":"Navarra SV, Guzm\u00e1n RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial[J]. <i>Lancet<\/i>, 2011, 377(9767): 721\u2013731.","DOI":"10.1016\/S0140-6736(10)61354-2"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.29","doi-asserted-by":"publisher","unstructured":"Furie R, Petri M, Zamani O, et al. A phase \u2162, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus[J]. <i>Arthritis Rheum<\/i>, 2011, 63(12): 3918\u20133930.","DOI":"10.1002\/art.30613"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.30","doi-asserted-by":"publisher","unstructured":"D\u00f6rner T, Lipsky PE. Beyond pan-B-cell-directed therapy\u2014new avenues and insights into the pathogenesis of SLE[J]. <i>Nat Rev Rheumatol<\/i>, 2016, 12(11): 645\u2013657.","DOI":"10.1038\/nrrheum.2016.158"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.31","doi-asserted-by":"publisher","unstructured":"Pavlasova G, Mraz M. The regulation and function of CD20: an \"enigma\" of B-cell biology and targeted therapy[J]. <i>Haematologica<\/i>, 2020, 105(6): 1494\u20131506.","DOI":"10.3324\/haematol.2019.243543"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.32","doi-asserted-by":"publisher","unstructured":"Clark EA, Giltiay NV. CD22: a regulator of innate and adaptive B cell responses and autoimmunity[J]. <i>Front Immunol<\/i>, 2018, 9: 2235.","DOI":"10.3389\/fimmu.2018.02235"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.33","doi-asserted-by":"publisher","unstructured":"Ere\u00f1o-Orbea J, Sicard T, Cui H, et al. Molecular basis of human CD22 function and therapeutic targeting[J]. <i>Nat Commun<\/i>, 2017, 8(1): 764.","DOI":"10.1038\/s41467-017-00836-6"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.34","doi-asserted-by":"publisher","unstructured":"Macauley MS, Pfrengle F, Rademacher C, et al. Antigenic liposomes displaying CD22 ligands induce antigen-specific B cell apoptosis[J]. <i>J Clin Invest<\/i>, 2013, 123(7): 3074\u20133083.","DOI":"10.1172\/JCI69187"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.35","doi-asserted-by":"publisher","unstructured":"Daridon C, Blassfeld D, Reiter K, et al. Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosus[J]. <i>Arthritis Res Ther<\/i>, 2010, 12(6): R204.","DOI":"10.1186\/ar3179"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.36","doi-asserted-by":"publisher","unstructured":"Du FH, Mills EA, Mao-Draayer Y. Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment[J]. <i>Autoimmun Highlights<\/i>, 2017, 8(1): 12.","DOI":"10.1007\/s13317-017-0100-y"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.37","doi-asserted-by":"publisher","unstructured":"Shipa M, Embleton-Thirsk A, Parvaz M, et al. Effectiveness of belimumab after rituximab in systemic lupus erythematosus[J]. <i>Ann Intern Med<\/i>, 2021, 174(12): 1647\u20131657.","DOI":"10.7326\/M21-2078"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.38","doi-asserted-by":"publisher","unstructured":"Li X, Ding Y, Zi M, et al. CD19, from bench to bedside[J]. <i>Immunol Lett<\/i>, 2017, 183: 86\u201395.","DOI":"10.1016\/j.imlet.2017.01.010"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.39","doi-asserted-by":"publisher","unstructured":"Esp\u00e9li M, Smith KGC, Clatworthy MR. Fc\u03b3RIIB and autoimmunity[J]. <i>Immunol Rev<\/i>, 2016, 269(1): 194\u2013211.","DOI":"10.1111\/imr.12368"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.40","doi-asserted-by":"publisher","unstructured":"Horton HM, Chu SY, Ortiz EC, et al. Antibody-mediated coengagement of Fc\u03b3RIIb and B cell receptor complex suppresses humoral immunity in systemic lupus erythematosus[J]. <i>J Immunol<\/i>, 2011, 186(7): 4223\u20134233.","DOI":"10.4049\/jimmunol.1003412"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.41","doi-asserted-by":"crossref","unstructured":"Merrill J, June J, Koumpouras F, et al. FRI0176 phase 2, double-blind, randomized, placebo-controlled study of a reversible b cell inhibitor, Xmab\u00ae5871, in systemic lupus erythematosus (SLE)[J]. <i>Ann Rheum Dis<\/i>, 2019, 78(Suppl 2): 761\u2013762.","DOI":"10.1136\/annrheumdis-2019-eular.4234"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.42","doi-asserted-by":"publisher","unstructured":"Accapezzato D, Caccavale R, Paroli MP, et al. Advances in the pathogenesis and treatment of systemic lupus erythematosus[J]. <i>Int J Mol Sci<\/i>, 2023, 24(7): 6578.","DOI":"10.3390\/ijms24076578"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.43","doi-asserted-by":"publisher","unstructured":"Chen P, Tsokos GC. T cell abnormalities in the pathogenesis of systemic lupus erythematosus: an update[J]. <i>Curr Rheumatol Rep<\/i>, 2021, 23(2): 12.","DOI":"10.1007\/s11926-020-00978-5"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.44","doi-asserted-by":"publisher","unstructured":"Shah D, Kiran R, Wanchu A, et al. Oxidative stress in systemic lupus erythematosus: relationship to Th1 cytokine and disease activity[J]. <i>Immunol Lett<\/i>, 2010, 129(1): 7\u201312.","DOI":"10.1016\/j.imlet.2010.01.005"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.45","doi-asserted-by":"publisher","unstructured":"Akahoshi M, Nakashima H, Tanaka Y, et al. Th1\/Th2 balance of peripheral T helper cells in systemic lupus erythematosus[J]. <i>Arthritis Rheum<\/i>, 1999, 42(8): 1644\u20131648.","DOI":"10.1002\/1529-0131(199908)42:8<1644::AID-ANR12>3.0.CO;2-L"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.46","doi-asserted-by":"publisher","unstructured":"Sugimoto K, Morimoto S, Kaneko H, et al. Decreased IL-4 producing CD4<sup>+<\/sup> T cells in patients with active systemic lupus erythematosus-relation to IL-12R expression[J]. <i>Autoimmunity<\/i>, 2002, 35(6): 381\u2013387.","DOI":"10.1080\/0891693021000008535"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.47","doi-asserted-by":"publisher","unstructured":"Paroli M, Caccavale R, Fiorillo MT, et al. The double game played by Th17 cells in infection: host defense and immunopathology[J]. <i>Pathogens<\/i>, 2022, 11(12): 1547.","DOI":"10.3390\/pathogens11121547"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.48","doi-asserted-by":"publisher","unstructured":"L\u00f3pez P, Rodr\u00edguez-Carrio J, Caminal-Montero L, et al. A pathogenic IFN\u03b1, BLyS and IL-17 axis in systemic lupus erythematosus patients[J]. <i>Sci Rep<\/i>, 2016, 6: 20651.","DOI":"10.1038\/srep20651"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.49","doi-asserted-by":"publisher","unstructured":"Zickert A, Amoudruz P, Sundstr\u00f6m Y, et al. IL-17 and IL-23 in lupus nephritis\u2014association to histopathology and response to treatment[J]. <i>BMC Immunol<\/i>, 2015, 16(1): 7.","DOI":"10.1186\/s12865-015-0070-7"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.50","doi-asserted-by":"publisher","unstructured":"Li M, Luo L, Wu Y, et al. Elevated apoptosis and abnormal apoptosis signaling of regulatory T cells in patients with systemic lupus erythematosus[J]. <i>Lupus<\/i>, 2022, 31(12): 1441\u20131455.","DOI":"10.1177\/09612033221119455"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.51","doi-asserted-by":"publisher","unstructured":"Tsai YG, Liao P, Hsiao KH, et al. Pathogenesis and novel therapeutics of regulatory T cell subsets and interleukin-2 therapy in systemic lupus erythematosus[J]. <i>Front Immunol<\/i>, 2023, 14: 1230264.","DOI":"10.3389\/fimmu.2023.1230264"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.52","doi-asserted-by":"publisher","unstructured":"He J, Zhang R, Shao M, et al. Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial[J]. <i>Ann Rheum Dis<\/i>, 2020, 79(1): 141\u2013149.","DOI":"10.1136\/annrheumdis-2019-215396"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.53","doi-asserted-by":"publisher","unstructured":"Miao M, Xiao X, Tian J, et al. Therapeutic potential of targeting Tfr\/Tfh cell balance by low-dose-IL-2 in active SLE: a post hoc analysis from a double-blind RCT study[J]. <i>Arthritis Res Ther<\/i>, 2021, 23(1): 167.","DOI":"10.1186\/s13075-021-02535-6"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.54","doi-asserted-by":"publisher","unstructured":"Mueller DL, Jenkins MK, Schwartz RH. Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy[J]. <i>Annu Rev Immunol<\/i>, 1989, 7: 445\u2013480.","DOI":"10.1146\/annurev.iy.07.040189.002305"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.55","doi-asserted-by":"publisher","unstructured":"McCoy KD, Le Gros G. The role of CTLA-4 in the regulation of T cell immune responses[J]. <i>Immunol Cell Biol<\/i>, 1999, 77(1): 1\u201310.","DOI":"10.1046\/j.1440-1711.1999.00795.x"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.56","doi-asserted-by":"publisher","unstructured":"Sharabi A, Tsokos GC. T cell metabolism: new insights in systemic lupus erythematosus pathogenesis and therapy[J]. <i>Nat Rev Rheumatol<\/i>, 2020, 16(2): 100\u2013112.","DOI":"10.1038\/s41584-019-0356-x"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.57","doi-asserted-by":"publisher","unstructured":"Pimentel-Quiroz VR, Ugarte-Gil MF, Alarc\u00f3n GS. Abatacept for the treatment of systemic lupus erythematosus[J]. <i>Expert Opin Investig Drugs<\/i>, 2016, 25(4): 493\u2013499.","DOI":"10.1517\/13543784.2016.1154943"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.58","doi-asserted-by":"publisher","unstructured":"Danion F, Rosine N, Belkhir R, et al. Efficacy of abatacept in systemic lupus erythematosus: a retrospective analysis of 11 patients with refractory disease[J]. <i>Lupus<\/i>, 2016, 25(13): 1440\u20131447.","DOI":"10.1177\/0961203316640911"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.59","doi-asserted-by":"publisher","unstructured":"Bezalel S, Guri KM, Elbirt D, et al. Type I interferon signature in systemic lupus erythematosus[J]. <i>Isr Med Assoc J<\/i>, 2014, 16(4): 246\u2013249.","DOI":"10.1111\/imj.12391"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.60","doi-asserted-by":"publisher","unstructured":"O'Shea JJ, Plenge R. JAK and STAT signaling molecules in immunoregulation and immune-mediated disease[J]. <i>Immunity<\/i>, 2012, 36(4): 542\u2013550.","DOI":"10.1016\/j.immuni.2012.03.014"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.61","doi-asserted-by":"publisher","unstructured":"de Veer MJ, Holko M, Frevel M, et al. Functional classification of interferon-stimulated genes identified using microarrays[J]. <i>J Leukoc Biol<\/i>, 2001, 69(6): 912\u2013920.","DOI":"10.1189\/jlb.69.6.912"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.62","doi-asserted-by":"publisher","unstructured":"Christensen SR, Shupe J, Nickerson K, et al. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus[J]. <i>Immunity<\/i>, 2006, 25(3): 417\u2013428.","DOI":"10.1016\/j.immuni.2006.07.013"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.63","doi-asserted-by":"crossref","unstructured":"Tanaka Y, Tago F, Yamakawa N, et al. A new therapeutic target for systemic lupus erythematosus: the current landscape for drug development of a toll-like receptor 7\/8 antagonist through academia-industry-government collaboration[J]. <i>Immunol Med<\/i>, 2023, 47(1): 24\u201329.","DOI":"10.1080\/25785826.2023.2264023"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.64","doi-asserted-by":"publisher","unstructured":"Furie R, Khamashta M, Merrill JT, et al. Anifrolumab, an anti-interferon-\u03b1 receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus[J]. <i>Arthritis Rheumatol<\/i>, 2017, 69(2): 376\u2013386.","DOI":"10.1002\/art.39962"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.65","doi-asserted-by":"publisher","unstructured":"Koenig KF, Groeschl I, Pesickova SS, et al. Serum cytokine profile in patients with active lupus nephritis[J]. <i>Cytokine<\/i>, 2012, 60(2): 410\u2013416.","DOI":"10.1016\/j.cyto.2012.07.004"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.66","doi-asserted-by":"publisher","unstructured":"Mok MY, Wu HJ, Lo Y, et al. The relation of interleukin 17 (IL-17) and IL-23 to Th1\/Th2 cytokines and disease activity in systemic lupus erythematosus[J]. <i>J Rheumatol<\/i>, 2010, 37(10): 2046\u20132052.","DOI":"10.3899\/jrheum.100293"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.67","doi-asserted-by":"publisher","unstructured":"Mok MY, Huang FP, Ip WK, et al. Serum levels of IL-33 and soluble ST2 and their association with disease activity in systemic lupus erythematosus[J]. <i>Rheumatology<\/i>, 2010, 49(3): 520\u2013527.","DOI":"10.1093\/rheumatology\/kep402"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.68","doi-asserted-by":"publisher","unstructured":"Pellerin A, Otero K, Czerkowicz JM, et al. Anti-BDCA2 monoclonal antibody inhibits plasmacytoid dendritic cell activation through Fc-dependent and Fc-independent mechanisms[J]. <i>EMBO Mol Med<\/i>, 2015, 7(4): 464\u2013476.","DOI":"10.15252\/emmm.201404719"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.69","doi-asserted-by":"publisher","unstructured":"Furie RA, van Vollenhoven RF, Kalunian K, et al. Trial of anti-BDCA2 antibody litifilimab for systemic lupus erythematosus[J]. <i>N Engl J Med<\/i>, 2022, 387(10): 894\u2013904.","DOI":"10.1056\/NEJMoa2118025"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.70","doi-asserted-by":"publisher","unstructured":"Cho SK, Vazquez T, Werth VP. Litifilimab (BIIB059), a promising investigational drug for cutaneous lupus erythematosus[J]. <i>Expert Opin Investig Drugs<\/i>, 2023, 32(5): 345\u2013353.","DOI":"10.1080\/13543784.2023.2212154"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.71","doi-asserted-by":"publisher","unstructured":"Karnell JL, Wu Y, Mittereder N, et al. Depleting plasmacytoid dendritic cells reduces local type I interferon responses and disease activity in patients with cutaneous lupus[J]. <i>Sci Transl Med<\/i>, 2021, 13(595): eabf8442.","DOI":"10.1126\/scitranslmed.abf8442"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.72","doi-asserted-by":"publisher","unstructured":"Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase \u2161\/\u2162 systemic lupus erythematosus evaluation of rituximab trial[J]. <i>Arthritis Rheum<\/i>, 2010, 62(1): 222\u2013233.","DOI":"10.1002\/art.27233"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.73","doi-asserted-by":"publisher","unstructured":"Kamburova EG, Koenen HJPM, Borgman KJE, et al. A single dose of rituximab does not deplete B cells in secondary lymphoid organs but alters phenotype and function[J]. <i>Am J Transplant<\/i>, 2013, 13(6): 1503\u20131511.","DOI":"10.1111\/ajt.12220"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.74","doi-asserted-by":"publisher","unstructured":"Tedder TF, Engel P. CD20: a regulator of cell-cycle progression of B lymphocytes[J]. <i>Immunol Today<\/i>, 1994, 15(9): 450\u2013454.","DOI":"10.1016\/0167-5699(94)90276-3"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.75","doi-asserted-by":"publisher","unstructured":"June CH, Sadelain M. Chimeric antigen receptor therapy[J]. <i>N Engl J Med<\/i>, 2018, 379(1): 64\u201373.","DOI":"10.1056\/NEJMra1706169"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.76","doi-asserted-by":"publisher","unstructured":"Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer[J]. <i>Science<\/i>, 2015, 348(6230): 62\u201368.","DOI":"10.1126\/science.aaa4967"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.77","doi-asserted-by":"publisher","unstructured":"Ledford H. The race to supercharge cancer-fighting T cells[J]. <i>Nature<\/i>, 2023, 613(7945): 626\u2013628.","DOI":"10.1038\/d41586-023-00177-z"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.78","doi-asserted-by":"publisher","unstructured":"Ganeeva I, Zmievskaya E, Valiullina A, et al. Recent advances in the development of bioreactors for manufacturing of adoptive cell immunotherapies[J]. <i>Bioengineering<\/i>, 2022, 9(12): 808.","DOI":"10.3390\/bioengineering9120808"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.79","doi-asserted-by":"publisher","unstructured":"Titov A, Kaminskiy Y, Ganeeva I, et al. Knowns and unknowns about CAR-T cell dysfunction[J]. <i>Cancers<\/i>, 2022, 14(4): 1078.","DOI":"10.3390\/cancers14041078"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.80","doi-asserted-by":"publisher","unstructured":"Valiullina AK, Zmievskaya EA, Ganeeva IA, et al. Evaluation of CAR-T cells' cytotoxicity against modified solid tumor cell lines[J]. <i>Biomedicines<\/i>, 2023, 11(2): 626.","DOI":"10.3390\/biomedicines11020626"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.81","doi-asserted-by":"publisher","unstructured":"Kansal R, Richardson N, Neeli I, et al. Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus[J]. <i>Sci Transl Med<\/i>, 2019, 11(482): eaav1648.","DOI":"10.1126\/scitranslmed.aav1648"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.82","doi-asserted-by":"publisher","unstructured":"Jin X, Xu Q, Pu C, et al. Therapeutic efficacy of anti-CD19 CAR-T cells in a mouse model of systemic lupus erythematosus[J]. <i>Cell Mol Immunol<\/i>, 2021, 18(8): 1896\u20131903.","DOI":"10.1038\/s41423-020-0472-1"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.83","doi-asserted-by":"publisher","unstructured":"Mougiakakos D, Kr\u00f6nke G, V\u00f6lkl S, et al. CD19-targeted CAR T cells in refractory systemic lupus erythematosus[J]. <i>N Engl J Med<\/i>, 2021, 385(6): 567\u2013569.","DOI":"10.1056\/NEJMc2107725"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.84","doi-asserted-by":"publisher","unstructured":"Tovey MG, Lallemand C. Immunogenicity and other problems associated with the use of biopharmaceuticals[J]. <i>Ther Adv Drug Saf<\/i>, 2011, 2(3): 113\u2013128.","DOI":"10.1177\/2042098611406318"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.85","doi-asserted-by":"publisher","unstructured":"Kuriakose A, Chirmule N, Nair P. Immunogenicity of biotherapeutics: causes and association with posttranslational modifications[J]. <i>J Immunol Res<\/i>, 2016, 2016: 1298473.","DOI":"10.1155\/2016\/1298473"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.86","doi-asserted-by":"publisher","unstructured":"Mullard A. CAR T cell therapies raise hopes\u2014and questions\u2014for lupus and autoimmune disease[J]. <i>Nat Rev Drug Discov<\/i>, 2023, 22(11): 859\u2013861.","DOI":"10.1038\/d41573-023-00166-x"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.87","doi-asserted-by":"publisher","unstructured":"Chasov V, Zaripov M, Mirgayazova R, et al. Promising new tools for targeting p53 mutant cancers: humoral and cell-based immunotherapies[J]. <i>Front Immunol<\/i>, 2021, 12: 707734.","DOI":"10.3389\/fimmu.2021.707734"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.88","doi-asserted-by":"publisher","unstructured":"Chames P, Van Regenmortel M, Weiss E, et al. Therapeutic antibodies: successes, limitations and hopes for the future[J]. <i>Br J Pharmacol<\/i>, 2009, 157(2): 220\u2013233.","DOI":"10.1111\/j.1476-5381.2009.00190.x"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.89","doi-asserted-by":"publisher","unstructured":"Almagro JC, Daniels-Wells TR, Perez-Tapia SM, et al. Progress and challenges in the design and clinical development of antibodies for cancer therapy[J]. <i>Front Immunol<\/i>, 2018, 8: 1751.","DOI":"10.3389\/fimmu.2017.01751"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.90","doi-asserted-by":"publisher","unstructured":"Neelapu SS. CAR-T efficacy: is conditioning the key?[J]. <i>Blood<\/i>, 2019, 133(17): 1799\u20131800.","DOI":"10.1182\/blood-2019-03-900928"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.91","doi-asserted-by":"publisher","unstructured":"Sun Y, Yuan Y, Zhang B, et al. CARs: a new approach for the treatment of autoimmune diseases[J]. <i>Sci China Life Sci<\/i>, 2023, 66(4): 711\u2013728.","DOI":"10.1007\/s11427-022-2212-5"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.92","doi-asserted-by":"publisher","unstructured":"Xiang S, Qu Y, Qian S, et al. Association between systemic lupus erythematosus and disruption of gut microbiota: a meta-analysis[J]. <i>Lupus Sci Med<\/i>, 2022, 9(1): e000599.","DOI":"10.1136\/lupus-2021-000599"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.93","doi-asserted-by":"publisher","unstructured":"Chen B, Jia X, Xu J, et al. An autoimmunogenic and proinflammatory profile defined by the gut microbiota of patients with untreated systemic lupus erythematosus[J]. <i>Arthritis Rheumatol<\/i>, 2021, 73(2): 232\u2013243.","DOI":"10.1002\/art.41511"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.94","doi-asserted-by":"publisher","unstructured":"Azzouz D, Omarbekova A, Heguy A, et al. Lupus nephritis is linked to disease-activity associated expansions and immunity to a gut commensal[J]. <i>Ann Rheum Dis<\/i>, 2019, 78(7): 947\u2013956.","DOI":"10.1136\/annrheumdis-2018-214856"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.95","doi-asserted-by":"publisher","unstructured":"van der Meulen TA, Harmsen HJM, Vila AV, et al. Shared gut, but distinct oral microbiota composition in primary Sj\u00f6gren's syndrome and systemic lupus erythematosus[J]. <i>J Autoimmun<\/i>, 2019, 97: 77\u201387.","DOI":"10.1016\/j.jaut.2018.10.009"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.96","doi-asserted-by":"publisher","unstructured":"Hevia A, Milani C, L\u00f3pez P, et al. Intestinal dysbiosis associated with systemic lupus erythematosus[J]. <i>mBio<\/i>, 2014, 5(5): e01548\u201314.","DOI":"10.1128\/mBio.01548-14"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.97","doi-asserted-by":"publisher","unstructured":"He J, Chan T, Hong X, et al. Microbiome and metabolome analyses reveal the disruption of lipid metabolism in systemic lupus erythematosus[J]. <i>Front Immunol<\/i>, 2020, 11: 1703.","DOI":"10.3389\/fimmu.2020.01703"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.98","doi-asserted-by":"publisher","unstructured":"Manfredo Vieira S, Hiltensperger M, Kumar V, et al. Translocation of a gut pathobiont drives autoimmunity in mice and humans[J]. <i>Science<\/i>, 2018, 359(6380): 1156\u20131161.","DOI":"10.1126\/science.aar7201"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.99","doi-asserted-by":"publisher","unstructured":"Zhang H, Liao X, Sparks JB, et al. Dynamics of gut microbiota in autoimmune lupus[J]. <i>Appl Environ Microbiol<\/i>, 2014, 80(24): 7551\u20137560.","DOI":"10.1128\/AEM.02676-14"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.100","doi-asserted-by":"publisher","unstructured":"Mu Q, Tavella VJ, Kirby JL, et al. Antibiotics ameliorate lupus-like symptoms in mice[J]. <i>Sci Rep<\/i>, 2017, 7(1): 13675.","DOI":"10.1038\/s41598-017-14223-0"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.101","doi-asserted-by":"publisher","unstructured":"Kim JW, Kwok SK, Choe JY, et al. Recent advances in our understanding of the link between the intestinal microbiota and systemic lupus erythematosus[J]. <i>Int J Mol Sci<\/i>, 2019, 20(19): 4871.","DOI":"10.3390\/ijms20194871"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.102","doi-asserted-by":"publisher","unstructured":"Mu Q, Kirby J, Reilly CM, et al. Leaky gut as a danger signal for autoimmune diseases[J]. <i>Front Immunol<\/i>, 2017, 8: 598.","DOI":"10.3389\/fimmu.2017.00598"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.103","doi-asserted-by":"publisher","unstructured":"Toumi E, Mezouar S, Plauzolles A, et al. Gut microbiota in SLE: from animal models to clinical evidence and pharmacological perspectives[J]. <i>Lupus Sci Med<\/i>, 2023, 10(1): e000776.","DOI":"10.1136\/lupus-2022-000776"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.104","doi-asserted-by":"publisher","unstructured":"Lei Y, Liu Q, Li Q, et al. Exploring the complex relationship between microbiota and systemic lupus erythematosus[J]. <i>Curr Rheumatol Rep<\/i>, 2023, 25(6): 107\u2013116.","DOI":"10.1007\/s11926-023-01102-z"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.105","doi-asserted-by":"publisher","unstructured":"Assimakopoulos SF, Triantos C, Thomopoulos K, et al. Gut-origin sepsis in the critically ill patient: pathophysiology and treatment[J]. <i>Infection<\/i>, 2018, 46(6): 751\u2013760.","DOI":"10.1007\/s15010-018-1178-5"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.106","doi-asserted-by":"publisher","unstructured":"Martin-Gallausiaux C, Larraufie P, Jarry A, et al. Butyrate produced by commensal bacteria down-regulates <i>Indolamine 2, 3-Dioxygenase 1<\/i> (<i>IDO-1<\/i>) expression <i>via<\/i> a dual mechanism in human intestinal epithelial cells[J]. <i>Front Immunol<\/i>, 2018, 9: 2838.","DOI":"10.3389\/fimmu.2018.02838"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.107","doi-asserted-by":"publisher","unstructured":"Rodr\u00edguez-Carrio J, L\u00f3pez P, S\u00e1nchez B, et al. Intestinal dysbiosis is associated with altered short-chain fatty acids and serum-free fatty acids in systemic lupus erythematosus[J]. <i>Front Immunol<\/i>, 2017, 8: 23.","DOI":"10.3389\/fimmu.2017.00023"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.108","doi-asserted-by":"publisher","unstructured":"Wu J, Pang T, Lin Z, et al. The key player in the pathogenesis of environmental influence of systemic lupus erythematosus: Aryl hydrocarbon receptor[J]. <i>Front Immunol<\/i>, 2022, 13: 965941.","DOI":"10.3389\/fimmu.2022.965941"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.109","doi-asserted-by":"publisher","unstructured":"Blank M, Barzilai O, Shoenfeld Y. Molecular mimicry and auto-immunity[J]. <i>Clin Rev Allergy Immunol<\/i>, 2007, 32(1): 111\u2013118.","DOI":"10.1007\/BF02686087"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.110","doi-asserted-by":"publisher","unstructured":"Greiling TM, Dehner C, Chen X, et al. Commensal orthologs of the human autoantigen Ro60 as triggers of autoimmunity in lupus[J]. <i>Sci Transl Med<\/i>, 2018, 10(434): eaan2306.","DOI":"10.1126\/scitranslmed.aan2306"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.111","doi-asserted-by":"publisher","unstructured":"He Z, Kong X, Shao T, et al. Alterations of the gut microbiota associated with promoting efficacy of prednisone by bromofuranone in MRL\/lpr mice[J]. <i>Front Microbiol<\/i>, 2019, 10: 978.","DOI":"10.3389\/fmicb.2019.00978"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.112","doi-asserted-by":"publisher","unstructured":"Luo XM, Edwards MR, Mu Q, et al. Gut microbiota in human systemic lupus erythematosus and a mouse model of lupus[J]. <i>Appl Environ Microbiol<\/i>, 2018, 84(4): e02288-17.","DOI":"10.1128\/AEM.02288-17"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.113","doi-asserted-by":"publisher","unstructured":"Guo M, Wang H, Xu S, et al. Alteration in gut microbiota is associated with dysregulation of cytokines and glucocorticoid therapy in systemic lupus erythematosus[J]. <i>Gut Microbes<\/i>, 2020, 11(6): 1758\u20131773.","DOI":"10.1080\/19490976.2020.1768644"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.114","doi-asserted-by":"publisher","unstructured":"Sch\u00e4fer AL, Eichhorst A, Hentze C, et al. Low dietary fiber intake links development of obesity and lupus pathogenesis[J]. <i>Front Immunol<\/i>, 2021, 12: 696810.","DOI":"10.3389\/fimmu.2021.696810"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.115","doi-asserted-by":"publisher","unstructured":"Zhang Y, Liu Q, Yu Y, et al. Early and short-term interventions in the gut microbiota affects lupus severity, progression, and treatment in MRL\/lpr mice[J]. <i>Front Microbiol<\/i>, 2020, 11: 628.","DOI":"10.3389\/fmicb.2020.00628"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.116","doi-asserted-by":"publisher","unstructured":"Mu Q, Cabana-Puig X, Mao J, et al. Pregnancy and lactation interfere with the response of autoimmunity to modulation of gut microbiota[J]. <i>Microbiome<\/i>, 2019, 7(1): 105.","DOI":"10.1186\/s40168-019-0720-8"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.117","doi-asserted-by":"publisher","unstructured":"Wang W, Fan Y, Wang X. <i>Lactobacillus<\/i>: friend or foe for systemic lupus erythematosus?[J]. <i>Front Immunol<\/i>, 2022, 13: 883747.","DOI":"10.3389\/fimmu.2022.883747"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.118","doi-asserted-by":"publisher","unstructured":"L\u00f3pez P, de Paz B, Rodr\u00edguez-Carrio J, et al. Th17 responses and natural IgM antibodies are related to gut microbiota composition in systemic lupus erythematosus patients[J]. <i>Sci Rep<\/i>, 2016, 6: 24072.","DOI":"10.1038\/srep24072"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.119","doi-asserted-by":"publisher","unstructured":"Mike A, Nagaoka N, Tagami Y, et al. Prevention of B220<sup>+<\/sup> T cell expansion and prolongation of lifespan induced by <i>Lactobacillus casei<\/i> in MRL\/lpr mice[J]. <i>Clin Exp Immunol<\/i>, 2001, 117(2): 368\u2013375.","DOI":"10.1046\/j.1365-2249.1999.00951.x"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.120","doi-asserted-by":"publisher","unstructured":"Mu Q, Zhang H, Liao X, et al. Control of lupus nephritis by changes of gut microbiota[J]. <i>Microbiome<\/i>, 2017, 5(1): 73.","DOI":"10.1186\/s40168-017-0300-8"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.121","doi-asserted-by":"publisher","unstructured":"Mardani F, Mahmoudi M, Esmaeili SA, et al. In vivo study: Th1\u2013Th17 reduction in pristane-induced systemic lupus erythematosus mice after treatment with tolerogenic <i>Lactobacillus<\/i> probiotics[J]. <i>J Cell Physiol<\/i>, 2019, 234(1): 642\u2013649.","DOI":"10.1002\/jcp.26819"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.122","doi-asserted-by":"crossref","unstructured":"Zeng W, Shen J, Bo T, et al. Cutting edge: probiotics and fecal microbiota transplantation in immunomodulation[J]. <i>J Immunol Res<\/i>, 2019, 2019: 1603758.","DOI":"10.1155\/2019\/1603758"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.123","doi-asserted-by":"publisher","unstructured":"Surawicz CM, Brandt LJ, Binion DG, et al. Guidelines for diagnosis, treatment, and prevention of <i>Clostridium difficile<\/i> infections[J]. <i>Am J Gastroenterol<\/i>, 2013, 108(4): 478\u2013498.","DOI":"10.1038\/ajg.2013.4"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.124","doi-asserted-by":"publisher","unstructured":"Wang M, Zhu Z, Lin X, et al. Gut microbiota mediated the therapeutic efficacies and the side effects of prednisone in the treatment of MRL\/lpr mice[J]. <i>Arthritis Res Ther<\/i>, 2021, 23(1): 240.","DOI":"10.1186\/s13075-021-02620-w"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.125","doi-asserted-by":"publisher","unstructured":"Johnson BM, Gaudreau MC, Al-Gadban MM, et al. Impact of dietary deviation on disease progression and gut microbiome composition in lupus-prone SNF1 mice[J]. <i>Clin Exp Immunol<\/i>, 2015, 181(2): 323\u2013337.","DOI":"10.1111\/cei.12609"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.126","doi-asserted-by":"crossref","unstructured":"Moayyedi P, Surette MG, Kim PT, et al. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial[J]. <i>Gastroenterology<\/i>, 2015, 149(1): 102\u2013109. e6.","DOI":"10.1053\/j.gastro.2015.04.001"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.127","doi-asserted-by":"publisher","unstructured":"de Groot P, Nikolic T, Pellegrini S, et al. Faecal microbiota transplantation halts progression of human new-onset type 1 diabetes in a randomised controlled trial[J]. <i>Gut<\/i>, 2021, 70(1): 92\u2013105.","DOI":"10.1136\/gutjnl-2020-322630"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.128","doi-asserted-by":"crossref","unstructured":"Zamudio Tiburcio \u00c1. Improvement in a patient with active systemic lupus erythematosous treated with transplant of intestinal microbiota[J]. <i>Gastroenterol Med Res<\/i>, 2019, 3(1): 1\u20134.","DOI":"10.31031\/GMR.2019.03.000551"},{"key":"10.7555\/JBR.38.20240009.swyxyjzzywb.129","doi-asserted-by":"publisher","unstructured":"Cammarota G, Ianiro G, Kelly CR, et al. International consensus conference on stool banking for faecal microbiota transplantation in clinical practice[J]. <i>Gut<\/i>, 2019, 68(12): 2111\u20132121.","DOI":"10.1136\/gutjnl-2019-319548"}],"container-title":["The Journal of Biomedical Research"],"original-title":[],"deposited":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T08:51:09Z","timestamp":1737708669000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jbr-pub.org.cn\/article\/doi\/10.7555\/JBR.38.20240009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":129,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024]]}},"alternative-id":["JBR-2024-0009"],"URL":"https:\/\/doi.org\/10.7555\/jbr.38.20240009","relation":{},"ISSN":["1674-8301","1674-8301"],"issn-type":[{"value":"1674-8301","type":"print"},{"value":"1674-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]}}}